Customize your JAMA Network experience by selecting one or more topics from the list below.
Kitley and colleagues aim to characterize the features of patients with neuromyelitis optica (NMO)/NMO spectrum disorder with myelin-oligodendrocyte glycoprotein (MOG) antibodies and compare them with patients with aquaporin-4 (AQP4) antibody–positive NMO/NMOSD.
Continuing Medical Education
Richardson and coauthors evaluate the association between serum levels of dichlorodiphenyldichloroethylene and Alzheimer disease (AD) and whether the apolipoprotein genotype modifies the association.
Chan et al examine deep brain stimulation use in Parkinson disease to determine which factors, among a variety of demographic, clinical, and socioeconomic variables, drive deep brain stimulation use in the United States.
Hedström and colleagues investigate the possible influence of alcohol consumption on the risk of developing multiple sclerosis and relate the influence of alcohol to the effect of smoking.
Ascherio and coauthors aim to determine whether serum concentrations of 25-hydroxyvitamin D, a marker of vitamin D status, predict disease activity and prognosis in patients with a first event suggestive of multiple sclerosis (clinically isolated syndrome).
Vardarajan et al determine the incidence rates of dementia and Alzheimer disease in unaffected family members in the National Institute on Aging Genetics Initiative for Late-Onset Alzheimer Disease/National Cell Repository for Alzheimer Disease and Estudio Familiar de Influencia Genetica en Alzheimer family studies.
Mealy and colleagues compare the relapse and treatment failure rates among patients receiving immunosuppression for neuromyelitis optica.
Devenney and coauthors aim to determine the frequency of the C9ORF72 mutation in a frontotemporal dementia (FTD) cohort and to define the clinical, neuropsychological, behavioral, and imaging features of C9ORF72 mutation carriers in comparison with noncarriers in a well-defined behavioral variant–FTD cohort.
Witting and Vissing analyze current information on the effect of pharmacologic treatment of downstream of tyrosine kinase 7 (DOK7) congenital myasthenic syndrome, which is one of the most common subtypes of this syndrome.
Tassone discusses the inclusion of fragile X syndrome in newborn screening.
Highlights. JAMA Neurol. 2014;71(3):251–253. doi:https://doi.org/10.1001/jamaneurol.2013.4136
Create a personal account or sign in to: